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Transdermal nicotine patches have been used in smoking cessation therapy, suggested for the treatment 
of skin disorders with eosinophilic infiltration and have been found to improve attention performance in 
patients with Alzheimer’s disease and age-associated memory impairment. However, skin irritation with 
extended patch use is still a problem. The aim of this work was to develop a simple to prepare liquid 
crystalline system containing vitamin E TPGS that would be able to control nicotine delivery and reduce 
irritation and sensitization problems. The liquid crystalline phases were macroscopically characterized by 
visual analysis and examined microscopically under a polarized light microscope. Topical and transdermal 
delivery of nicotine were investigated in vitro using porcine ear skin mounted on a Franz diffusion cell. 
Nicotine skin permeation from the developed cubic phase followed zero-order kinetics (r = 0.993) and 
was significantly enhanced after 12 h when compared to the control formulation (nicotine solution) 
(p < 0.05) (138.86 ± 20.44 and 64.91 ± 4.06 μg/cm2, respectively). Cubic phase was also able to target 
viable skin layers in comparison to control solution (8.18 ± 1.89 and 2.63 ± 2.51 μg/cm2, respectively). 
Further studies to evaluate skin sensitization and irritation are now necessary.
Uniterms: Nicotine/transdermal patches. Nicotine/controlled transdermal delivery. Liquid crystalline 
systems/development. Vitamin E TPGS. Skin irritation/control/in vitro study. Skin irritation/use of 
transdermal patches.
Adesivos transdérmicos de nicotina são utilizados para cessação de fumar, tratamento de problemas de 
pele com infiltração de eosinófilos e para melhorar a atenção em pacientes com doença de Alzheimer e 
enfraquecimento da memória associada à idade. No entanto, a irritação da pele com o uso prolongado 
dos adesivos ainda é um problema. O objetivo deste trabalho foi desenvolver sistema líquido cristalino 
(SLC) de preparo simples contendo vitamina E TPGS capaz de controlar a liberação de nicotina e reduzir 
os problemas de irritação cutânea. Os SLCs foram caracterizados por análise visual e microscopia de luz 
polarizada. As administrações tópica e transdérmica de nicotina foram investigadas in vitro utilizando pele 
de orelha de porco em célula de difusão de Franz. A permeação da nicotina veiculada pela fase cúbica 
desenvolvida seguiu cinética de ordem zero (r = 0,993) e foi significativamente maior do que o controle 
(solução de nicotina) após 12 h (p < 0,05) (138,86 ± 20,44 e 64,91 ± 4,06 µg/cm2, respectivamente). A 
fase cúbica também promoveu aumento da penetração de nicotina nas camadas viáveis da pele quando 
comparado ao controle (8,18 ± 1,89 e 2,63 ± 2,51 µg/cm2, respectivamente). Estudos futuros para avaliar 
a sensibilização e irritação da pele são necessários.
Unitermos: Nicotina/adesivos transdérmicos. Nicotina/liberação controlada. Vitamina E TPGS. Irritação 
cutânea/controle/estudo in vitro. Irritação cutânea/uso de adesivos transdérmicos.
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INTRODUCTION
Nicotine use in smoking cessation therapy is already 
well established. It is clinically demonstrated that constant 
plasma level reduces the craving for smoking. Marketed 
formulations containing nicotine include chewing gums, 
transdermal patches, nasal sprays, inhalers and sublingual 
tablets/lozenges (Stead et al., 2012). Still, adverse effects 
are related to all of these administration forms: chewing 
gums may cause dyspepsia and jaw ache; nasal sprays may 
cause sneezing and coughing and inhalers may also lead 
to coughing (Karnath, 2002). Nasal and sublingual forms 
are commonly related to mucosal irritation while both 
irritation and sensitization reactions are often described as 
reactions to transdermal patch applications (Levin, 1995; 
Stead et al., 2012). Such adverse effects can be mild and 
manageable for short therapy time periods, however, they 
can decrease patient compliance in longer treatments, 
which is exactly the main problem with current nicotine 
replacement therapies. 
Recent studies suggest that extended therapies for 
24 weeks may be more advantageous than 8 weeks, as it 
attenuates weight gain, reduces the risk for smoking lapses 
and increases the likelihood of recovery to abstinence 
after a lapse (Schnoll et al., 2010; Schnoll, Wileyto, 
Lerman, 2012). Besides the use in smoking cessation, 
novel applications for nicotine are suggested. Although its 
use for symptom control in advanced Parkinson’s disease 
presents inconclusive results (Villafane et al., 2014), 
chronic transdermal nicotine has been found to improve 
attention performance in patients with Alzheimer’s 
disease and age-associated memory impairment (White, 
Levin, 2004). Transdermal nicotine patches have also 
been suggested for the treatment of skin disorders with 
eosinophilic infiltration such as Kimura’s disease, 
erythema nodosum and eosinophilic pustular folliculitis 
(Yoshifuku et al., 2013).
With all these new options and therapies regimen 
emerging, it is imperative to develop novel formulations 
able to control delivery and reduce irritation and 
sensitization problems. 
Nicotine is theoretically a good penetrant in the 
skin; it has low molecular weight and high solubility in 
both polar and non-polar solvents (Zorin, Kuylenstierna, 
Thulin, 1999) (Figure 1). However, nicotine is a reactive 
liquid and a potent solvent that can degrade commonly 
used patch materials. Resistant polymers, normally allow 
high nicotine permeability, making drug retention within 
the system a problem (Davaran et al., 2005). 
Liquid crystalline systems can be mainly classified 
into lamellar, cubic, and hexagonal phases according 
to their different internal structures. They represent 
interesting vehicles to be used for skin topical delivery 
as they can simultaneously protect and improve drug 
characteristics and interact with the skin favoring drug 
permeation and tissue recovery. Several studies show that 
such systems normally do not cause skin irritation after 
topical application (Esposito et al., 2005; Dong et al., 
2006; Lopes, Speretta, Bentley, 2007). Moreover, their 
highly ordered internal structures offer the potential for 
slow drug release (Chen, Ma, Gui, 2014). Indeed, liquid 
crystalline systems have shown to improve the topical/
transdermal delivery of many drugs (Bender et al., 2005, 
2008; Peng et al., 2010; Kravchenko, Boyko, Novikova, 
2011; Aeinleng et al., 2012). 
The dominating internal structure and in vivo 
performance is notably dependent on the components of 
the liquid crystalline system and the proportions of each 
material in the formulation. Tocopheryl polyethylene 
glycol succinate (TPGS) is a non-ionic water-soluble 
derivative of vitamin E having an HLB value of 13.2. 
Chemically, it is D-α-tocopheryl polyethylene glycol 
1000 succinate possessing a hydrophilic (PEG) head and a 
lipophilic (phytyl) tail. TPGS is reported to increase poorly 
absorbed drugs bioavailability due to its solubilizing effect 
through micelle formation (Aggarwal, Goindi, Mehta, 
2012). It has been applied as a solubilizer, an emulsifier, 
absorption/permeation enhancer, plasticizer, bioadhesive, 
and as a vehicle in lipid-based drug delivery formulations 
(Aggarwal, Goindi, Mehta, 2012). Due to its excellent 
safety profile it has been employed in this study.
Therefore, the aim of this work was to develop a 
liquid crystalline system containing vitamin E TPGS for 
the controlled transdermal nicotine delivery. 
MATERIAL AND METHODS
Material
Nicotine ((–)-nicotine ([–]-1-methyl-2-[3-pyridyl-
pyrrolidine])) was purchased from SIGMA Chemical Co 
(St Louis, USA). Vitamin E TPGS (d-alpha-tocopheryl 
polyethylene glycol 1000 succinate) was supplied 
by Eastman (Kingsport, Tennessee, USA), isopropyl 
myristate (IPM) from Vetec (Rio de Janeiro, Brazil) and 
FIGURE 1 - Nicotine chemical structure (MW 162.23).
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propylene glycol (PG) from Synth (Diadema, Brazil). 
Glacial acid acetic was obtained from Merck (Darmstadt, 
Germany), diethylamine from Rieder-de-Haen (Seelze, 
Germany). Sodium phosphate monobasic and sodium 
phosphate dibasic were from Synth (Diadema, Brazil). 
Methanol and acetonitrile, both high-performance liquid 
chromatography (HPLC) grade were from Vetec (Rio 
de Janeiro, Brazil) and J.T. Baker (USA), respectively. 
Solutions or mobile phase mixtures were prepared with 
water purified in a Milli-Q-plus System (Millipore, 
Bedforte, MA, USA).
Octanol/Water and Octanol/Buffer partition 
coefficient
Water saturated with octanol and octanol saturated 
with water was first obtained by stirring a mixture of 
water/octanol at ratio 1:1 (v/v) for 1 h followed by funnel 
separation. An appropriate amount of nicotine, to obtain a 
final concentration of 5.0 mg/mL, was added to the water 
phase in a test tube. The tube was shaken overnight. Thus, 
the solution was filtered and divided into two fractions. 
One was quantified by HPLC (C1 – before partition). The 
other was added in oil phase at the ratio 1:1 (v/v) and then 
they were shaked for one hour. The phases were again 
separated. Concentrations of nicotine present in the water 
phase were determined by HPLC (C2 – after partition). 
The experiment was performed in triplicate. The partition 
coefficient Ko/w was determined according to equation 1:
  (1)
where, Ko/w is octanol/water partition coefficient; C1 is 
nicotine concentration in the water phase before partition 
and C2 is nicotine concentration in the water phase after 
partition.
The determination of partition coefficient oil/buffer 
followed the same method described for determining 
the partition coefficient oil/water. The aqueous phase 
consisted of 0.15 M phosphate buffer pH 7.2.
Formulation preparation
Liquid crystalline phases were prepared as 
previously described by Vicentini et al. (2008). To obtain 
the systems, mixtures of surfactant (Vitamin E TPGS) and 
oil (IPM) were prepared in different ratios (3:1, 1:1 and 1:3 
(w/w)), which were diluted with a mixture of water and 
PG following the same ratio. These systems were shaken 
in a mixer to obtain a homogeneous formulation, and 
stored in closed vials for four days to reach equilibrium. 
Nicotine was added as a solution to the aqueous phase. 
The percentage of nicotine in the formulations was 
0.25% (w/v).
Characterization of the liquid crystal phases
Liquid crystalline phases were macroscopically 
characterized by visual  analysis  and examined 
microscopically under a polarized light microscope 
(Axioplan 2 Image Pol microscope, Carl Zeiss, Oberkichen, 
Germany) after the equilibrium was reached.
Skin
Porcine ear skin obtained from a local slaughterhouse. 
Porcine ears were obtained soon after the sacrifice of the 
animal, before the scalding process. The whole skin was 
removed from the outer region of the ear, separated from 
its underlying layer with scissors, dermatomized to 1 mm 
thickness and stored frozen at -20 °C for a maximum of 1 
month before use.
In vitro skin permeation
The penetration of nicotine in the skin and its 
percutaneous delivery were evaluated in an in vitro model 
using porcine ear skin, as previously described (Herai 
et al., 2007; Gratieri et al., 2014). Briefly, the skin was 
thawed and mounted in a Franz diffusion cell (diffusion 
area of 1.77 cm2; Hanson Instruments, Chatsword, CA), 
with the stratum corneum facing upwards the donor 
compartment. Receptor compartment was filled with 
0.15 M phosphate buffer (pH 7.2), and maintained at 37 °C 
under constant stirring (300 rpm). 
One hundred and fifty milligrams of lamellar or 
cubic phase containing 0.25% of nicotine (PG-H2O 
(3:1): VitE TPGS-IPM (3:1) at 20:80 and 50:50, w/w, 
respectively) were applied on skin surface. One hundred 
and fifty microliters of nicotine solution 2.5 mg/mL 
were used as control. To determine the concentration of 
permeated nicotine 1 mL of receptor solution samples were 
collected at 0, 15, 30 min, 1, 2, 4, 8, 12 h and analyzed 
by HPLC. At 12 h post-application of liquid crystals 
formulation, skin surfaces were carefully washed with 
distilled water to remove excess formulation. To separate 
the stratum corneum (SC) from the remaining epidermis 
(E) and dermis (D), skin sections were subjected to tape 
stripping. The skin was stripped with 5 pieces of adhesive 
tape, the first one was discarded, and the others ones 
containing the SC were immersed in 2 mL methanol, 
vortex stirred for 3 min and the methanolic phase filtered 
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using a 0.45 μm membrane. The remaining [E + D] were 
cut in small pieces, vortex for 3 min in 1 mL of methanol, 
and bath sonicated for 30 min. The resulting mixture was 
then filtered using a 0.45 μm membrane, and nicotine 
was assayed in the filtrate by HPLC as described above. 
Nicotine recovery from SC and E+D was previously 
validated and showed error percentages within the limits 
accepted for validation of methods involving extractive 
processes (± 15%).
Kinetic evaluation
Results were plotted as the mean cumulative amount 
of drug released/permeated per unit of surface area against 
time. Different kinetic models were evaluated:
Zero-order model (concentration against time): 
Qt = Q0 + K0 t;
Higuchi’s model (concentration against square root 
of time):
Qt / Q0 = KH t1/2,
First order model (logarithm of the concentration 
against time):
log Qt = log Q0 + K1 t
where Qt is the amount diffused (µg) at time t (h), Q0 is 
the initial amount in the donor compartment (µg). K0 is the 
zero-order constant (µg h-1), KH is the first order constant 
(µg h-1), and K1 is the Higuchi’s constant (µg h1/2). The 
correlation coefficient (r) for each kinetic model was 
calculated to determine the best fit model.
Analytical analysis
Nicotine was quantified by an analytical method 
using a high performance liquid chromatograph (HPLC) 
Shimadzu LC-10A VP, coupled to a spectrophotometric 
detector (model SPD-10A VP) and a computer equipped 
with the chromatographic analysis program Shimadzu LC. 
Analytical method was based on a previously described 
methodology (Pereira, Marchetti, Bentley, 2001). Briefly, 
a reverse-phase column (Lichrospher® 100 RP-18 column 
(5 μm; Merck), equipped with a RP-18 precolumn (Merck) 
was used as stationary phase, and mobile phase consisted 
of a mixture of water, methanol, acetonitrile, glacial acid 
acetic and diethylamine at 93.55:3:2:1:0.45 (v/v/v/v/v). 
The mobile phase flow rate was 1 mL/min, the sample 
injection volume was 50 μL and detection was made at 
254 nm. The method was validated in terms of linearity, 
precision, accuracy, specificity/selectivity and limit of 
quantification, according to current Brazilian legislation 
(ANVISA, 2003). The regression line equation calculated 
by the least-squares method was y = 75.42 x + 73 with 
a correlation coefficient (r) of 0.9976. Accuracy and 
precision were, respectively, 5.51% and 6.66%. Method 
limit of quantification (LOQ) was 0.4 μg/mL.
Data analyses
At least four replicates of each transport experiment 
were performed. Results are presented as mean ± standard 
deviation (SD) and expressed in terms of nicotine amount 
per unit area of skin (μg/cm2). Data were statistically 
analyzed by one way ANOVA, followed by Bonferroni´s 
multiple comparisons t-test. Statistical significance was 
fixed at p < 0.05.
RESULTS
Octanol/Water and Octanol/Buffer partition 
coefficient
The partition coefficients were determined according 
to equation 1. The octanol/water and octanol/buffer 
partition coefficient was found to be 3.45 (± 0.21) and 3.51 
(± 0.09), respectively. This means a Log P approximately 
of 0.54. 
Preparation and characterization of the liquid 
crystal phases
The phase diagram of systems containing Vitamin 
E TPGS, IPM and PG-H2O in 1:3 ratio is demonstrated 
in Figure 2. The ternary diagram shows that when the 
aqueous phase comprises a lower percentage than 30% 
the formation of liquid crystalline phase as lamellar, 
cubic and hexagonal phase are favored. In the range of 30 
to 50% of aqueous phase, cubic phase is obtained when 
the concentration of Vit E TPGS is greater than or equal 
to the concentration of IPM, and, when the Vit E TPGS 
concentration is lower than the IPM concentration liquid 
crystalline system are not formed, rather forming a simple 
emulsion. Emulsion is also formed when the percentage 
of aqueous phase in the system is greater than or equal to 
60%. 
The association of Vitamin E TPGS, IPM and 
PG-water in the ratio 1:1 and 3:1 has been previously 
demonstrated (Vicentini et al., 2008). Polarized light 
microcopy analysis is shown in Figure 3.
After liquid crystalline phases preparation, the 
effect of nicotine on the systems phase behavior was 
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analyzed. The maximum amount of nicotine that allows 
the formation of liquid crystalline phases was evaluated by 
adding nicotine at 0.25%, 0.5%, 1.0% and 2.0% (w/v) into 
the most stable systems. The results illustrated in Table I 
indicated that only at 0.2% of nicotine it was possible to 
obtain liquid crystalline phases. 
The Figure 4A, 4B and 4C show the phase diagrams 
of systems containing the PG:H2O components at 3:1, 1:1, 
1:3 ratios with 0.25% (w/v) of nicotine.
Diagrams show that the presence of nicotine can 
interfere in the formation of liquid crystalline phases. 
Some cubic and hexagonal phases obtained without 
nicotine were able to maintain their structure even after 
drug incorporation, however, many structures were 
affected by nicotine addiction. On the other hand, lamellar 
phases structures were maintained. 
The formulation composed of Vitamin E TPGS/
IPM/PG-H2O (3:1) at 37.5:7.5:37.5:7.5 w/w/w/w, which 
was characterized as cubic phase, maintained its structure 
after drug incorporation. Conversely, the formulation 
FIGURE 2 - Phase diagram of Vitamin E TPGS/IPM/PG-H2O 
systems at 1:3 ratio. The phase regions are: filled circle hexagonal 
phase, filled square emulsion, filled triangle unstable emulsion, 
empty circle cubic phase, empty square lamellar phase, empty 
triangle isotropic liquid, gray circle cubic phase+water.
FIGURE 3 - Photomicrographs by polarized light microscopy. (A) Hexagonal phase composed of Vitamin E TPGS/IPM/PG-H2O 
(3:1) at 67.5:22.5:7.5:2.5 w/w/w/w; (B) Unstable emulsion composed of Vitamin E TPGS/IPM/PG-H2O (1:1) at 7.5:22.5:35:35 
w/w/w/w, (C) Lamellar phase composed of Vitamin E TPGS/IPM/PG-H2O (1:1) at 60:20:10:10 w/w/w/w and (D) Cubic phase 
(cubic phase+water) composed of Vitamin E TPGS/IPM/PG-H2O (1:3) at 22.5:67.5:2.5:7.5 w/w/w/w. Increase 200X.
TABLE I - Structural identification by visual analyses and polarized light microscopy of different formulations
System
Nicotine concentration (w/v %)
0.0 0.25 0.5 1.0 2.0
5 (PG:H2O-3:1) : 5 (Vit E: IPM–3:1) Cubic Phase Cubic Phase - - -
1 (PG:H2O-1:1) : 9 (Vit E: IPM–3:1) Lamellar Phase - - - -
1(PG:H2O-3:1) : 9 (Vit E: IPM–3:1) Hexagonal + 
Cubic Phase
- - - -
4.5 (PG:H2O-3:1) : 5.5 (Vit E: IPM–1:3) Emulsion - - - -
2 (PG:H2O-3:1) : 8 (Vit E: IPM–3:1) Hexagonal + 
Cubic Phase
Lamellar Phase Isotropic 
Liquid
Isotropic 
Liquid
Isotropic 
Liquid
1 (PG:H2O-1:3) : Lamellar Phase - Isotropic 
Liquid
Isotropic 
Liquid
Isotropic 
Liquid
PG: propylene glycol; Vit E: Vitamin E TPGS; IPM: isopropyl myristate; (-): did not form liquid crystalline phase.
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composed of Vitamin E TPGS/IPM/PG-H2O (3:1) 
at 15:5:60:20 w/w/w/w was characterized as cubic + 
hexagonal phase and turned into a lamellar phase internal 
structure upon drug incorporation. The influence of these 
liquid crystalline phases on nicotine permeation through 
the skin was evaluated.
In vitro skin penetration and percutaneous 
delivery
Cubic phase system significantly enhanced nicotine 
skin penetration after 12 h, compared to the control 
formulation (nicotine solution) (p < 0.05). 
The cumulative amount of permeated nicotine for 
12 h was 138.86 ± 20.44 μg/cm2 (65.54% of the initial 
content) and 64.91 ± 4.06 μg/cm2 (30.64% of the initial 
content) when, respectively, cubic phase and control 
solution were applied.
Even though lamellar phase system promoted a 
faster permeation at first hours, there was no significant 
difference in the total drug amount permeated when the 
lamellar system was applied (153.47 ± 14.22 μg/cm2, 
representing 72.44% of the initial content) compared to 
the cubic phase (p > 0.05) (Figure 5). Cubic phase system 
was the only formulation studied able to control nicotine 
permeation following a zero order kinetics (r = 0.993), 
while drug permeation from the lamellar phase system 
and control solution followed Higuchi kinetics (r = 0.972 
and 0.994, respectively). 
Incorpora t ion  of  n icot ine  in  the  lamel lar 
phase promoted greater drug penetration in the SC 
FIGURE 4 - Phase diagrams of Vitamin E TPGS/IPM/PG-H2O 
systems at (A) 3:1, (B) 1:1 and (C) 1:3 ratios with 0.25% (w/v) 
of nicotine. The phase regions are: filled circle birrefringence, 
filled square emulsion, filled triangle unstable emulsion, 
empty circle cubic phase, empty square lamellar phase, empty 
triangle isotropic liquid, gray circle cubic phase+water, gray 
square cubic phase+hexagonal phase, gray triangle hexagonal 
phase+water.
FIGURE 5 - Time-course of the in vitro skin penetration of 
nicotine incorporated into different formulations. The number 
of replicates is 4 per experimental group. *p < 0.05 compared 
to control.
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(5.87 ± 2.37 μg/cm2) and [E+D] (13.82 ± 0.70 μg/cm2) 
compared to the control (1.17 ± 0.26 μg/cm2 and 
2.63 ± 2.51 μg/cm2 , respectively) (p < 0.05), while the 
cubic phase was able to target [E+D] (8.18 ± 1.89 μg/cm2) 
compared to the control (p < 0.05), maintaining similar SC 
amounts (1.34 ± 0.41 μg/cm2) than the control solution 
(p > 0.05) (Figure 6).
 
DISCUSSION
In the current study, the potential application of 
cubic and lamellar phases of Vitamin E TPGS, IPM, PG 
and water as a topical delivery system of nicotine was 
demonstrated. Since Vitamin E TPGS has a lipophilic 
alkyl tail (polyethylene glycol) and a hydrophilic polar 
head portion (tocopherol succinate), it appears to be a 
promising molecule to obtain liquid crystalline systems 
(Aggarwal, Goindi, Mehta, 2012).
The diagrams presented in Figure 4 show that the 
presence of nicotine can interfere with the formation 
of some liquid crystalline phases. Several authors also 
noticed changes in the liquid crystalline phase due to the 
addition of drugs and solvents. The characteristics of the 
additives determine their location at the polar or apolar 
domains of the systems, which can affect the molecular 
packing and promote phase transition. Hydrophilic or 
charged compounds favor the phase change from cubic 
to lamellar phase, while non-polar compounds favor 
cubic and hexagonal phase formation (Kumar et al., 
2004; Liu et al., 2013; Engstrom, Engstrom, 1992). 
The addition of nicotine to the formulation composed 
of Vitamin E TPGS/IPM/PG-H2O (3:1) at 15:5:60:20 
w/w/w/w favored the change from cubic to lamellar 
phase corroborating the literature (Liu et al., 2013; 
Engstrom, Engstrom, 1992). On the other hand, the 
presence of nicotine at 0.25% did not affect the liquid 
crystalline system formed by Vitamin E TPGS/IPM/
PG-H2O (3:1) at 37.5:7.5:37.5:7.5 w/w/w/w, which 
maintained its cubic phase. Therefore, the presence and 
amount of all components influence molecular packing 
parameters, determining the type of liquid crystalline 
system formed. Hence, it is important to characterize 
the formulation because liquid crystalline structure may 
influence the drug release (Guo et al., 2010). 
To evaluate if liquid crystalline phase of Vitamin E 
TPGS, IPM, PG and water can act as topical/transdermal 
system for the controlled delivery of nicotine, skin 
percutaneous delivery of nicotine incorporated in the 
cubic and lamellar phase were studied in comparison to 
a control solution. Incorporation of nicotine in the cubic 
phase promoted increase in the nicotine permeation 
compared with the control and followed a zero-order 
kinetics, meaning that the cubic phase formulation was 
able to control nicotine delivery for 12 h. Lamellar phase 
system was able to promote a faster permeation at first 
hours. Nonetheless, the total drug amount permeated 
from either lamellar or cubic phases after 12 h did not 
present significant statistical difference (p > 0.05). Cubic 
phase system was also able to target the viable epidermis 
[E+D], but did not influence the penetration through the 
SC compared with the control solution. Several studies 
showed that liquid crystalline phases are greater for 
topical delivery compared with solutions (Lim et al., 
2014, Bender et al., 2008) corroborating with the present 
results. Still, cubic phase penetration pathways into 
the skin have been poorly studied. Bender et al. (2008) 
proposed that cubic phase penetrates into skin mainly 
by micro-fissures, from which hydrophilic compounds 
diffuse into the surrounding intercellular lipid matrix 
being a source for sustained release (Bender et al., 2008). 
In the present study, as shown above, the incorporation of 
nicotine in both lamellar and cubic phases enhanced the 
in vitro permeation and penetration in the skin. A possible 
explanation may be the action of Vitamin E-TPGS and 
IPM as penetration enhancers (Guo et al., 2013; Aggarwal, 
Goindi, Mehta, 2012; Engelbrecht et al., 2012). Indeed, 
it has been reported that Vitamin E acts as a permeation 
enhancer by intercalating within the lipid bilayer region 
of the SC, promoting changes of membrane permeability 
(Trivedi, Krill, Fort, 1995), while IPM acts as penetration 
enhancer by introducing phase separation and perturbing 
the multilamellar lipid assembly (Engelbrecht et al., 2012). 
FIGURE 6 - In vitro skin penetration of nicotine at 12 h 
following topical application using cubic and lamellar phase 
systems containing 375 μg of nicotine or a control solution 
(2.5 mg/mL). SC: stratum corneum, [E+D]: epidermis (without 
SC) plus dermis. Results are represented be means ± S.D. (n = 4). 
* p < 0.05 compared to control.
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Besides the contribution of liquid crystalline 
structure in increasing the skin uptake of drugs, it is also 
important to consider the different performances of each 
particular structure. The differences observed in the in 
vitro skin penetration of nicotine incorporated in the cubic 
and lamellar phases may be related with the differences 
of the percentages constituents and can be explained 
by the partition coefficient. The octanol/water (3.45) or 
octanol/buffer (3.51) partition coefficient indicated that 
the nicotine, a hydrophilic drug, has great preference for 
water medium, so the cubic phase that have more water 
content was able to better control nicotine delivery. The 
lamellar phase, which has a higher percentage of oil phase, 
promoted a higher flux of nicotine through the skin at 
first hours, but not in a controlled fashion, reflected by 
the Higushi kinetics model. Accordingly, Carr, Corish, 
Corrigan (1997) studied the in vitro nicotine release from 
lyotropic liquid crystal gels obtained from Myverol. They 
observed that water increase in the vehicle would lead to 
an increased release flux, increasing its partitioning into 
the membrane (Carr, Corish, Corrigan, 1997).
As stated above, nicotine is a good penetrant in the 
skin; it has low molecular weight and high solubility in 
both polar and non-polar solvents (Zorin, Kuylenstierna, 
Thulin, 1999), therefore, high permeation percentages 
are expected. The real challenge is to develop a stable, 
biocompatible formulation that is able to control drug 
delivery in a predictable fashion. 
Delivery rates may vary enormously depending 
on formulation components. Mucoadhesive patches 
composed of xantham gum and Carbopol 934-based 
showed to release up to 98% and 39%, respectively, after 
10 h (Abu-Huwaij et al., 2011). 
In vitro comparative studies of two marketed 
transdermal nicotine delivery systems (Nicopatch® 
and Nicorette®) demonstrated that the cumulative 
amount of permeated nicotine was 709 ± 56 µg.cm-2 
(40% of the initial surface area content) at 24 h for 
Nicopatch and for Nicorette, it was 501 ± 39 µg cm-2 
(60% of the initial surface area content) at 16 h and 
717 ± 58 µg.cm-2 (86%) at 24 h (Olivier, Rabouan, 
Couet, 2003). Correspondingly, transdermal nicotine 
patches available in the Brazilian market, including 
a rate-controlling membrane device (15 cm2 of patch 
size containing 78 mg of drug) and a polymeric matrix 
device (20 cm2 of patch size containing 35 mg of drug) 
showed permeation rates of 41.7 ± 1.2 µg.cm-2.h-1 and 
38.3 ± 3.6 µg.cm-2.h-1, respectively (Ruela et al., 2013). 
Vitamin E TGPS cubic phase system developed promoted 
a lower cumulative amount of permeated nicotine per cm² 
and lower release rate (138.86 ± 20.44 μg.cm-2 after 12 h 
and 10.48 µg.cm-2.h-1) compared with marketed patches, 
but comparable released percentage amounts (65.54% of 
the initial content). Such differences are obviously related 
to the applied drug doses. Even though the cubic phase 
system have a drug loading limitation, as evidenced by 
the results reported in Table I, the developed cubic phase 
system can be easily applied to larger skin areas, while 
patches are applied from 10 cm2 to 20 cm2. Being the 
maximal applied area normally 20 cm2. 
Hence, the developed cubic phase system was able 
to achieve the task of controlling drug delivery. Skin 
irritation and sensitization studies to attest formulation 
safety are now necessary.
CONCLUSION
Developed Vitamin E TGPS cubic phase system 
is a simple formulation, formed with just the mixture of 
emulsifier, oil phase and water, which make its fabrication 
exceptionally easy, low cost, without the need for 
sophisticated equipment for preparation. The formulation 
was able to control drug delivery following zero-order 
kinetics. It is an interesting drug delivery system with 
potential to be used for extended smoking cessation 
therapy or other situations where systemic nicotine 
delivery is indicated. 
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